Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

Divergent antiviral effects of bioflavonoids on the hepatitis C virus life cycle.

Khachatoorian R, Arumugaswami V, Raychaudhuri S, Yeh GK, Maloney EM, Wang J, Dasgupta A, French SW.

Virology. 2012 Nov 25;433(2):346-55. doi: 10.1016/j.virol.2012.08.029.

2.

The heat shock protein inhibitor Quercetin attenuates hepatitis C virus production.

Gonzalez O, Fontanes V, Raychaudhuri S, Loo R, Loo J, Arumugaswami V, Sun R, Dasgupta A, French SW.

Hepatology. 2009 Dec;50(6):1756-64. doi: 10.1002/hep.23232.

3.

A cell-permeable hairpin peptide inhibits hepatitis C viral nonstructural protein 5A-mediated translation and virus production.

Khachatoorian R, Arumugaswami V, Ruchala P, Raychaudhuri S, Maloney EM, Miao E, Dasgupta A, French SW.

Hepatology. 2012 Jun;55(6):1662-72. doi: 10.1002/hep.25533.

4.

The regulation of hepatitis C virus (HCV) internal ribosome-entry site-mediated translation by HCV replicons and nonstructural proteins.

He Y, Yan W, Coito C, Li Y, Gale M Jr, Katze MG.

J Gen Virol. 2003 Mar;84(Pt 3):535-43.

PMID:
12604803
5.

Interleukin-29 suppresses hepatitis A and C viral internal ribosomal entry site-mediated translation.

Kanda T, Wu S, Kiyohara T, Nakamoto S, Jiang X, Miyamura T, Imazeki F, Ishii K, Wakita T, Yokosuka O.

Viral Immunol. 2012 Oct;25(5):379-86. doi: 10.1089/vim.2012.0021.

PMID:
23035851
6.

Interferon and ribavirin combination treatment synergistically inhibit HCV internal ribosome entry site mediated translation at the level of polyribosome formation.

Panigrahi R, Hazari S, Chandra S, Chandra PK, Datta S, Kurt R, Cameron CE, Huang Z, Zhang H, Garry RF, Balart LA, Dash S.

PLoS One. 2013 Aug 23;8(8):e72791. doi: 10.1371/journal.pone.0072791.

7.

Antiviral activity of four types of bioflavonoid against dengue virus type-2.

Zandi K, Teoh BT, Sam SS, Wong PF, Mustafa MR, Abubakar S.

Virol J. 2011 Dec 28;8:560. doi: 10.1186/1743-422X-8-560.

8.

Naringenin and quercetin--potential anti-HCV agents for NS2 protease targets.

Lulu SS, Thabitha A, Vino S, Priya AM, Rout M.

Nat Prod Res. 2016;30(4):464-8. doi: 10.1080/14786419.2015.1020490.

PMID:
25774442
9.

Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents.

Buckwold VE, Beer BE, Donis RO.

Antiviral Res. 2003 Sep;60(1):1-15. Review.

PMID:
14516916
10.

Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.

McGivern DR, Masaki T, Lovell W, Hamlett C, Saalau-Bethell S, Graham B.

J Virol. 2015 May;89(10):5362-70. doi: 10.1128/JVI.03188-14.

11.

Multiple effects of Honokiol on the life cycle of hepatitis C virus.

Lan KH, Wang YW, Lee WP, Lan KL, Tseng SH, Hung LR, Yen SH, Lin HC, Lee SD.

Liver Int. 2012 Jul;32(6):989-97. doi: 10.1111/j.1478-3231.2011.02621.x.

PMID:
22098176
12.

Sequence-specific cleavage of hepatitis C virus RNA by DNAzymes: inhibition of viral RNA translation and replication.

Roy S, Gupta N, Subramanian N, Mondal T, Banerjea AC, Das S.

J Gen Virol. 2008 Jul;89(Pt 7):1579-86. doi: 10.1099/vir.0.83650-0.

PMID:
18559927
13.

Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism.

Goldwasser J, Cohen PY, Lin W, Kitsberg D, Balaguer P, Polyak SJ, Chung RT, Yarmush ML, Nahmias Y.

J Hepatol. 2011 Nov;55(5):963-71. doi: 10.1016/j.jhep.2011.02.011.

14.

The NS5A-binding heat shock proteins HSC70 and HSP70 play distinct roles in the hepatitis C viral life cycle.

Khachatoorian R, Ganapathy E, Ahmadieh Y, Wheatley N, Sundberg C, Jung CL, Arumugaswami V, Raychaudhuri S, Dasgupta A, French SW.

Virology. 2014 Apr;454-455:118-27. doi: 10.1016/j.virol.2014.02.016.

15.

Suppression of hepatitis C virus by the flavonoid quercetin is mediated by inhibition of NS3 protease activity.

Bachmetov L, Gal-Tanamy M, Shapira A, Vorobeychik M, Giterman-Galam T, Sathiyamoorthy P, Golan-Goldhirsh A, Benhar I, Tur-Kaspa R, Zemel R.

J Viral Hepat. 2012 Feb;19(2):e81-8. doi: 10.1111/j.1365-2893.2011.01507.x.

PMID:
22239530
16.

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.

Guedj J, Dahari H, Rong L, Sansone ND, Nettles RE, Cotler SJ, Layden TJ, Uprichard SL, Perelson AS.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3991-6. doi: 10.1073/pnas.1203110110.

17.

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

McGivern DR, Masaki T, Williford S, Ingravallo P, Feng Z, Lahser F, Asante-Appiah E, Neddermann P, De Francesco R, Howe AY, Lemon SM.

Gastroenterology. 2014 Aug;147(2):453-62.e7. doi: 10.1053/j.gastro.2014.04.021.

18.

Measuring antiviral activity of benzimidazole molecules that alter IRES RNA structure with an infectious hepatitis C virus chimera expressing Renilla luciferase.

Liu S, Nelson CA, Xiao L, Lu L, Seth PP, Davis DR, Hagedorn CH.

Antiviral Res. 2011 Jan;89(1):54-63. doi: 10.1016/j.antiviral.2010.11.004.

19.

The hepatitis C virus life cycle as a target for new antiviral therapies.

Pawlotsky JM, Chevaliez S, McHutchison JG.

Gastroenterology. 2007 May;132(5):1979-98. Review.

PMID:
17484890
20.

Quercetin: bioflavonoids as part of interferon-free hepatitis C therapy?

Lu N, Khachatoorian R, French SW.

Expert Rev Anti Infect Ther. 2012 Jun;10(6):619-21. doi: 10.1586/eri.12.52. No abstract available.

PMID:
22734951
Items per page

Supplemental Content

Support Center